endostar  (Kisker Biotech)

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Patient general information.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Comparison of short-term efficacy among three groups.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques: Comparison

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: Progression-free survival curve of ENDOSTAR continuous infusion group, ENDOSTAR intravenous drip group and concurrent chemotherapy group. The curves depict the rates at which patients in each group maintained disease progression-free status over time since the commencement of treatment.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques: Biomarker Discovery

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: The overall survival curve of ENDOSTAR continuous infusion group, ENDOSTAR intravenous drip group and concurrent chemotherapy group. The curves reflect the survival conditions of patients in each group from the start of treatment until the end of follow-up.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: Frontiers in Medicine

Article Title: Clinical efficacy of Endostar continuous infusion combined with concurrent chemoradiotherapy in the treatment of oesophageal squamous cell carcinoma

doi: 10.3389/fmed.2024.1463041

Figure Lengend Snippet: The adverse reactions of 62 cases of esophageal carcinoma with different therapeutic schemes.

Article Snippet: Kisker ( ) found that after a single intraperitoneal injection of Endostar to mice, the drug in the tumor tissue was quickly cleared within 2 h. Moreover, continuous administration through a micro-osmotic pump can keep the blood drug concentration stable for a long time, and the same anti-tumor effect can be obtained with one-eighth of the dose of a single injection.

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: Baseline and clinical characteristics of patients and their correlation with Endostar

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The difference in the incidence of ≥ grade 2 RP at different subgroups

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques:

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The efficacy of endostar with NSCLC in previously reported studies

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques: Control

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: Clinical trials about Endostar combined with ICIs in NSCLC

Article Snippet: Tanabe et al [ ] found that endostatin suppressed peritoneal fibrosis by significantly reducing vascular endothelial growth factor A (VEGF-A), alpha-smooth muscle actin (α-SMA), and the pro-fibrotic factor TGF-β1 in a mouse model. Another investigation revealed that Endostar alleviated radiation-induced pulmonary alveolitis, pulmonary edema, fibrosis, and TGF-β1 release in mice compared to radiation-exposed mice treated without Endostar, suggesting that Endostar can reduce radiation-induced pulmonary lesions [ ].

Techniques: Clinical Proteomics

Journal: BMC Cancer

Article Title: Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy

doi: 10.1186/s12885-024-12001-6

Figure Lengend Snippet: The efficacy of endostar with NSCLC in previously reported studies

Article Snippet: Recombinant human endostatin (Endostar): In the CCRT + Endostar group, the administered dose of Endostar (Shandong Simcere-Medgenn Bio-pharmaceutical Co., LTD., trade name: Endostar, Sinopharm approved S20050088) was 7.5 mg/m 2 /day with 1–14 days of continuous administration.

Techniques: Control